Loading...
PEPG logo

PepGen Inc.NasdaqGS:PEPG Stock Report

Market Cap US$114.1m
Share Price
US$1.55
US$10.14
84.7% undervalued intrinsic discount
1Y0.6%
7D-11.9%
Portfolio Value
​
View

PepGen Inc.

NasdaqGS:PEPG Stock Report

Market Cap: US$114.1m

PepGen (PEPG) Stock Overview

A clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. More details

PEPG fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months compared to the US market

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years


PEPG Community Fair Values

Create Narrative

See what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

PepGen Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for PepGen
Historical stock prices
Current Share PriceUS$1.55
52 Week HighUS$7.80
52 Week LowUS$1.01
Beta2.01
1 Month Change-9.88%
3 Month Change-75.93%
1 Year Change0.65%
3 Year Change-89.21%
5 Year Changen/a
Change since IPO-87.98%

Recent News & Updates

Seeking Alpha • Mar 31

PepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some Relief

Summary PepGen Inc. shares plunged about 65% after mixed Phase 2 data for PGN-EDODM1 in DM1, with no functional improvement at 5 mg/kg. PGN-EDODM1 showed clean safety and biological activity, but efficacy was pretty modest and skewed by an outlier. So that higher 10 mg/kg dose is the next key catalyst. PEPG trades near cash value, reflecting heavy market skepticism on clinical success; the balance sheet supports operations through 2H26 and the next trial readout. I remain cautiously optimistic, awaiting 10 mg/kg data for clearer efficacy before considering new investment at these depressed levels. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Mar 31

PepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some Relief

Summary PepGen Inc. shares plunged about 65% after mixed Phase 2 data for PGN-EDODM1 in DM1, with no functional improvement at 5 mg/kg. PGN-EDODM1 showed clean safety and biological activity, but efficacy was pretty modest and skewed by an outlier. So that higher 10 mg/kg dose is the next key catalyst. PEPG trades near cash value, reflecting heavy market skepticism on clinical success; the balance sheet supports operations through 2H26 and the next trial readout. I remain cautiously optimistic, awaiting 10 mg/kg data for clearer efficacy before considering new investment at these depressed levels. Read the full article on Seeking Alpha
Analysis Article • Nov 19

Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jun 27

Here's Why We're A Bit Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Mar 04

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Nov 19

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Aug 06

PepGen (NASDAQ:PEPG) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 31

PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments

Summary PepGen Inc. achieved positive data from the phase 2 CONNECT1 study, using PGN-EDO51 for the treatment of exon 51 skipping DMD patients; higher 10 mg/kg dosing of drug data is expected in early 2025. The global Duchenne Muscular Dystrophy treatment market size is expected to reach $8.19 billion in 2029. PGN-EDO53 is another EDO drug being developed by the company, with the goal of targeting 8% of DMD patients amenable to exon 53 skipping. Update on the use of PGN-EDODM1, in the ongoing phase 1 FREEDOM-DM1 study, expected in Q4 of 2024; Positive update could move the program towards a phase 2 trial. Read the full article on Seeking Alpha
Seeking Alpha • May 20

The Prognosis For PepGen

Summary PepGen's stock has experienced extreme volatility, with an 80% drop, a 370% rebound, and subsequent decline in 14 months. The rebound was driven by news that Sarepta's DMD exon 51 candidate had lower skipping output than PepGen's PGN-EDO51. PepGen is focused on developing oligonucleotide therapies for severe neuromuscular and neurologic diseases, with two programs in human trials. A full investment analysis around PepGen follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Jan 20

PepGen: Long Road Ahead

Summary PepGen is using exon skipping therapies to address muscular dystrophy conditions, specifically Duchenne muscular dystrophy (DMD) and Myotonic dystrophy type 1 (DM1). They are developing PGN-EDO51 and PGN-EDODM1. The market sizes for these therapies are estimated to be around $1.3 billion for DMD and potentially up to $4.5 billion for DM1, but there are financial and operational risks involved. Valuation doesn't offer enough of a margin of safety. Read the full article on Seeking Alpha
Analysis Article • Nov 13

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Jul 31

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 31

We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

PEPGUS BiotechsUS Market
7D-11.9%-1.6%-0.9%
1Y0.6%34.4%24.4%

Return vs Industry: PEPG underperformed the US Biotechs industry which returned 40.3% over the past year.

Return vs Market: PEPG underperformed the US Market which returned 26.7% over the past year.

Price Volatility

Is PEPG's price volatile compared to industry and market?
PEPG volatility
PEPG Average Weekly Movement19.6%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.1%

Stable Share Price: PEPG's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: PEPG's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201856James McArthurwww.pepgen.com

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study.

PepGen Inc. Fundamentals Summary

How do PepGen's earnings and revenue compare to its market cap?
PEPG fundamental statistics
Market capUS$114.13m
Earnings (TTM)-US$77.22m
Revenue (TTM)n/a
0.0x
P/S Ratio
-1.4x
P/E Ratio

Is PEPG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PEPG income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$77.22m
Earnings-US$77.22m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-1.12
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did PEPG perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/15 02:55
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PepGen Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Debjit ChattopadhyayGuggenheim Securities, LLC
Ananda GhoshH.C. Wainwright & Co.